Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 136Unspecified Adult Solid Tumor, Protocol Specific 122Leukemia, Lymphocytic, Chronic, B-Cell 119Lymphoma 103Breast Neoplasms 102Neoplasms 99Lymphoma, Follicular 98Burkitt Lymphoma 98Lymphoma, Large B-Cell, Diffuse 97Lymphoma, Non-Hodgkin 94Leukemia, Myeloid, Acute 89Lymphoma, Mantle-Cell 88Lymphoma, B-Cell, Marginal Zone 81Neoplasm Metastasis 80Lymphoma, Large-Cell, Immunoblastic 73Carcinoma, Non-Small-Cell Lung 68Melanoma 64Hodgkin Disease 64Lymphoma, T-Cell, Cutaneous 63Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 60Lymphoma, Large-Cell, Anaplastic 60Lung Neoplasms 60Prostatic Neoplasms 58Brain Neoplasms 58Astrocytoma 57Mycosis Fungoides 55Colonic Neoplasms 55Glioblastoma 54Sezary Syndrome 52Ovarian Neoplasms 52

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NIH × Metaplasia × Clear all
NCT01013831 2015-02-18

Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung

National Cancer Institute (NCI)

Phase 1 Terminated
60 enrolled

Metaplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡